NRSN - NeuroSense Therapeutics Ltd.

QQQ $ 429.07 $ 5.38 (1.28 %)

DIA $ 382.31 $ 3.34 (0.88 %)

SPY $ 505.01 $ 4.68 (0.94 %)

TLT $ 88.87 $ 0.38 (0.43 %)

GLD $ 213.12 $ -0.66 (-0.31 %)

Previous Close

$ 1.27

Open

$ 1.27

Bid

$ 1.24 x 200

Ask

$ 0.00 x 0

Day's Range

$ 1.24 - $ 1.27

52 Week Range

$ 0.40 - $ 2.33

Volume

104,024

Average Volume

Market Cap

19.53M

Beta (5Y Monthly)

$ 1.22

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

NeuroSense shares are trading higher after...
04/22/2024 12:33:02

NeuroSense and Genetika+ Initiate Precisio...
04/22/2024 12:31:27

NeuroSense Presents Data Validating Phase ...
04/18/2024 12:34:24

Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consiste...

NeuroSense To Present PARADIGM Data At Ame...
04/12/2024 12:36:00

Reported Earlier, NeuroSense Therapeutics ...
04/11/2024 06:23:56

NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it ha...

NeuroSense Collaborates With Lonza To Iden...
04/09/2024 12:51:25

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neur...

NeuroSense Therapeutics Q4 EPS $(0.16) Bea...
04/05/2024 20:49:13

NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate ...

NeuroSense FY23 EPS $(0.83) Beats $(0.85) ...
04/05/2024 13:30:43

NeuroSense Reports Results From Its ALS Ph...
02/21/2024 13:32:21

PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALSSt...

NeuroSense Regains Nasdaq Compliance
02/07/2024 14:28:31

NeuroSense Reviews 2023 Achievements; Prov...
01/09/2024 13:46:34

End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 ...

NeuroSense Reveals Receipt Of Nasdaq Notic...
12/27/2023 22:01:49

NeuroSense has 45 days from the date of the notice, or until February 5, 2024, to submit to Nasdaq a plan to regain compliance ...

NeuroSense Reports Efficacy Data From Furt...
12/14/2023 14:28:49

A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with Pr...

Why AeroVironment Shares Are Trading Lower...
12/06/2023 19:43:02

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

us-stocks-higher-private-payrolls-rise-by-103000-in-november

US Stocks Higher; Private Payrolls Rise By...
12/06/2023 14:42:45

U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening W...

Why SentinelOne Shares Are Trading Higher ...
12/06/2023 13:32:03

Shares of SentinelOne, Inc. (NYSE: S) rose sharply in pre-market trading after the company reported stronger-than-expected res...

Why Daktronics Shares Are Trading Lower By...
12/05/2023 18:06:18

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

Why GitLab Shares Are Trading Higher By Ov...
12/05/2023 14:04:20

Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results ...

NeuroSense Announces It Met Its Primary Sa...
12/05/2023 13:14:48

NeuroSense Will Report New Data From Rando...
12/04/2023 21:02:54